Do analysts recommend POAI or HSDT?

Solana has a consensus target price of $3.50, suggesting a potential upside of 95.53%. Given Solana's stronger consensus rating and higher probable upside, analysts clearly believe Solana is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Solana 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is POAI or HSDT more profitable?

Solana has a net margin of -1,427.15% compared to Predictive Oncology's net margin of -5,065.23%. Solana's return on equity of -67.57% beat Predictive Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Predictive Oncology -5,065.23% -732.73% -235.55% Solana -1,427.15% -67.57% -24.09%

Do analysts rate INO or POAI?

Inovio Pharmaceuticals currently has a consensus target price of $4.25, suggesting a potential upside of 248.36%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Inovio Pharmaceuticals is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inovio Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer POAI or OM?

Outset Medical has a consensus price target of $10.00, suggesting a potential upside of 111.86%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts clearly believe Outset Medical is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Outset Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts recommend NRXS or POAI?

NeurAxis currently has a consensus target price of $13.00, suggesting a potential upside of 84.14%. Given NeurAxis' stronger consensus rating and higher possible upside, research analysts plainly believe NeurAxis is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Predictive Oncology (POAI) Competitors

$7.08 -0.14 (-1.94%)

As of 07/2/2026

Compare

POAI vs. LAKE, HSDT, INO, OM, and NRXS

Should you buy Predictive Oncology stock or one of its competitors? MarketBeat compares Predictive Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Predictive Oncology include Lakeland Industries (LAKE), Solana (HSDT), Inovio Pharmaceuticals (INO), Outset Medical (OM), and NeurAxis (NRXS). These companies are all part of the "medical equipment" industry.

How does Predictive Oncology compare to Lakeland Industries?

Lakeland Industries (NASDAQ:LAKE) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Lakeland Industries has a net margin of -10.87% compared to Predictive Oncology's net margin of -5,065.23%. Lakeland Industries' return on equity of -6.64% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakeland Industries	-10.87%	-6.64%	-4.13%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Lakeland Industries currently has a consensus target price of $16.00, suggesting a potential upside of 29.45%. Given Lakeland Industries' stronger consensus rating and higher probable upside, equities research analysts plainly believe Lakeland Industries is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakeland Industries	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

71.7% of Lakeland Industries shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 3.4% of Lakeland Industries shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Lakeland Industries' average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company	Overall Sentiment
Lakeland Industries	Neutral
Predictive Oncology	Neutral

Lakeland Industries has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

Predictive Oncology has lower revenue, but higher earnings than Lakeland Industries. Lakeland Industries is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakeland Industries	$192.65M	0.63	-$25.31M	-$2.13	N/A
Predictive Oncology	$1.66M	14.44	-$12.66M	-$13.50	N/A

Summary

Lakeland Industries beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.

How does Predictive Oncology compare to Solana?

Predictive Oncology (NASDAQ:POAI) and Solana (NASDAQ:HSDT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

In the previous week, Solana had 4 more articles in the media than Predictive Oncology. MarketBeat recorded 4 mentions for Solana and 0 mentions for Predictive Oncology. Solana's average media sentiment score of 0.77 beat Predictive Oncology's score of 0.00 indicating that Solana is being referred to more favorably in the news media.

Company	Overall Sentiment
Predictive Oncology	Neutral
Solana	Positive

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 18.6% of Solana shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 14.4% of Solana shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Predictive Oncology has higher earnings, but lower revenue than Solana. Predictive Oncology is trading at a lower price-to-earnings ratio than Solana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	14.44	-$12.66M	-$13.50	N/A
Solana	$6.02M	17.36	-$40.89M	-$109.67	N/A

Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Solana has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Solana has a consensus target price of $3.50, suggesting a potential upside of 95.53%. Given Solana's stronger consensus rating and higher probable upside, analysts clearly believe Solana is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Solana	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Solana has a net margin of -1,427.15% compared to Predictive Oncology's net margin of -5,065.23%. Solana's return on equity of -67.57% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Solana	-1,427.15%	-67.57%	-24.09%

Summary

Solana beats Predictive Oncology on 14 of the 17 factors compared between the two stocks.

How does Predictive Oncology compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

In the previous week, Inovio Pharmaceuticals' average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company	Overall Sentiment
Inovio Pharmaceuticals	Neutral
Predictive Oncology	Neutral

Inovio Pharmaceuticals currently has a consensus target price of $4.25, suggesting a potential upside of 248.36%. Given Inovio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Inovio Pharmaceuticals is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Predictive Oncology has higher revenue and earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	1,672.82	-$84.95M	-$1.45	N/A
Predictive Oncology	$1.66M	14.44	-$12.66M	-$13.50	N/A

Inovio Pharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Inovio Pharmaceuticals has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. Inovio Pharmaceuticals' return on equity of -489.79% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Summary

Inovio Pharmaceuticals beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.

How does Predictive Oncology compare to Outset Medical?

Predictive Oncology (NASDAQ:POAI) and Outset Medical (NASDAQ:OM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

9.0% of Predictive Oncology shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Comparatively, 2.5% of Outset Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Outset Medical has a net margin of -63.65% compared to Predictive Oncology's net margin of -5,065.23%. Outset Medical's return on equity of -56.13% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Outset Medical	-63.65%	-56.13%	-27.45%

Outset Medical has a consensus price target of $10.00, suggesting a potential upside of 111.86%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts clearly believe Outset Medical is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Outset Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Outset Medical has a beta of 1.95, meaning that its share price is 95% more volatile than the broader market.

In the previous week, Outset Medical had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 1 mentions for Outset Medical and 0 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 0.00 equaled Outset Medical'saverage media sentiment score.

Company	Overall Sentiment
Predictive Oncology	Neutral
Outset Medical	Neutral

Predictive Oncology has higher earnings, but lower revenue than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	14.44	-$12.66M	-$13.50	N/A
Outset Medical	$119.48M	0.73	-$81.65M	-$4.16	N/A

Summary

Outset Medical beats Predictive Oncology on 11 of the 15 factors compared between the two stocks.

How does Predictive Oncology compare to NeurAxis?

NeurAxis (NASDAQ:NRXS) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

NeurAxis currently has a consensus target price of $13.00, suggesting a potential upside of 84.14%. Given NeurAxis' stronger consensus rating and higher possible upside, research analysts plainly believe NeurAxis is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NeurAxis has a net margin of -492.76% compared to Predictive Oncology's net margin of -5,065.23%. NeurAxis' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

NeurAxis has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

In the previous week, NeurAxis' average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company	Overall Sentiment
NeurAxis	Neutral
Predictive Oncology	Neutral

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Predictive Oncology has lower revenue, but higher earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28M	20.42	-$14.63M	-$0.81	N/A
Predictive Oncology	$1.66M	14.44	-$12.66M	-$13.50	N/A

Summary

NeurAxis beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.

Get Predictive Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POAI vs. The Competition

Export

Metric	Predictive Oncology	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.03M	$1.83B	$7.16B	$12.48B
Dividend Yield	N/A	N/A	2.66%	6.52%
P/E Ratio	-0.52	81.75	28.02	24.70
Price / Sales	14.44	7.15	540.37	99.46
Price / Cash	N/A	26.08	49.26	57.09
Price / Book	-15.39	5.75	10.96	6.46
Net Income	-$12.66M	-$54.76M	$3.57B	$337.01M
7 Day Performance	-1.12%	2.95%	2.12%	1.69%
1 Month Performance	-13.34%	2.81%	5.25%	3.81%
1 Year Performance	-44.60%	-0.07%	33.29%	23.90%

Predictive Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POAI Predictive Oncology	N/A	$7.08 -1.9%	N/A	-44.6%	$24.03M	$1.66M	N/A	30
LAKE Lakeland Industries	3.0137 of 5 stars	$10.42 +6.7%	$16.00 +53.6%	-8.6%	$96.42M	$192.65M	N/A	2,600
HSDT Solana	3.9793 of 5 stars	$1.51 -7.4%	$3.50 +131.8%	-81.0%	$95.17M	$6.02M	N/A	30
INO Inovio Pharmaceuticals	1.8149 of 5 stars	$1.13 +1.8%	$4.25 +276.1%	-15.0%	$92.97M	N/A	N/A	320	Analyst Downgrade
OM Outset Medical	2.3919 of 5 stars	$4.76 -2.5%	$10.00 +110.1%	-77.3%	$90.46M	$119.48M	N/A	520	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:POAI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Predictive Oncology (POAI) Competitors

POAI vs. LAKE, HSDT, INO, OM, and NRXS

How does Predictive Oncology compare to Lakeland Industries?

Summary

How does Predictive Oncology compare to Solana?

Summary

How does Predictive Oncology compare to Inovio Pharmaceuticals?

Summary

How does Predictive Oncology compare to Outset Medical?

Summary

How does Predictive Oncology compare to NeurAxis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Predictive Oncology (POAI) Competitors

POAI vs. LAKE, HSDT, INO, OM, and NRXS

How does Predictive Oncology compare to Lakeland Industries?

Is LAKE or POAI more profitable?

Do analysts prefer LAKE or POAI?

Do institutionals & insiders believe in LAKE or POAI?

Does the media prefer LAKE or POAI?

Which has more risk & volatility, LAKE or POAI?

Which has stronger valuation & earnings, LAKE or POAI?

Summary

How does Predictive Oncology compare to Solana?

Does the media refer more to POAI or HSDT?

Do insiders and institutionals hold more shares of POAI or HSDT?

Which has higher valuation and earnings, POAI or HSDT?

Which has more risk & volatility, POAI or HSDT?

Do analysts recommend POAI or HSDT?

Is POAI or HSDT more profitable?

Summary

How does Predictive Oncology compare to Inovio Pharmaceuticals?

Does the media prefer INO or POAI?

Do analysts rate INO or POAI?

Which has better earnings & valuation, INO or POAI?

Which has more risk & volatility, INO or POAI?

Do institutionals and insiders hold more shares of INO or POAI?

Is INO or POAI more profitable?

Summary

How does Predictive Oncology compare to Outset Medical?

Do insiders and institutionals believe in POAI or OM?

Is POAI or OM more profitable?

Do analysts prefer POAI or OM?

Which has more risk & volatility, POAI or OM?

Does the media favor POAI or OM?

Which has preferable valuation and earnings, POAI or OM?

Summary

How does Predictive Oncology compare to NeurAxis?

Do analysts recommend NRXS or POAI?

Is NRXS or POAI more profitable?

Which has more risk & volatility, NRXS or POAI?

Does the media prefer NRXS or POAI?

Do institutionals and insiders hold more shares of NRXS or POAI?

Which has better valuation & earnings, NRXS or POAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools